These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32196923)

  • 1. Autologous stem cell transplant for high-risk neuroblastoma: Achieving cure with low-cost adaptations.
    Jain R; Hans R; Totadri S; Trehan A; Sharma RR; Menon P; Kapoor R; Saxena AK; Mittal BR; Bhatia P; Kakkar N; Srinivasan R; Rajwanshi A; Varma N; Samujh R; Marwaha N; Bansal D
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28273. PubMed ID: 32196923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta.
    Jain R; Trehan A; Menon P; Kapoor R; Kakkar N; Radhika S; Saxena AK; Mittal BR; Varma N; Samujh R; Bansal D
    Pediatr Hematol Oncol; 2021 May; 38(4):291-304. PubMed ID: 33622164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
    French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
    Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers.
    Elborai Y; Hafez H; Moussa EA; Hammad M; Hussein H; Lehmann L; Elhaddad A
    Pediatr Transplant; 2016 Mar; 20(2):284-9. PubMed ID: 26614402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
    Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Impacting Time to Engraftment in Patients With High-risk Neuroblastoma Following Autologous Stem Cell Transplant.
    Hillier K; Cheng WS; Whittle SB; Krance R; Foster JH
    J Pediatr Hematol Oncol; 2020 Oct; 42(7):e569-e574. PubMed ID: 32032244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
    Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
    Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.
    Proust-Houdemont S; Pasqualini C; Blanchard P; Dufour C; Benhamou E; Goma G; Semeraro M; Raquin MA; Hartmann O; Valteau-Couanet D
    Bone Marrow Transplant; 2016 Aug; 51(8):1076-81. PubMed ID: 27042850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution.
    Soni S; Pai V; Gross TG; Ranalli M
    Pediatr Transplant; 2014 Mar; 18(2):217-20. PubMed ID: 24341617
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Giardino S; Piccardo A; Conte M; Puntoni M; Bertelli E; Sorrentino S; Montera M; Risso M; Caviglia I; Altrinetti V; Lanino E; Faraci M; Garaventa A
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28775. PubMed ID: 33099289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.
    Pasqualini C; Dufour C; Goma G; Raquin MA; Lapierre V; Valteau-Couanet D
    Bone Marrow Transplant; 2016 Feb; 51(2):227-31. PubMed ID: 26524264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
    Gutierrez-Delgado F; Holmberg L; Hooper H; Petersdorf S; Press O; Maziarz R; Maloney D; Chauncey T; Appelbaum F; Bensinger W
    Bone Marrow Transplant; 2003 Aug; 32(3):279-85. PubMed ID: 12858199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
    Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
    Desai AV; Heneghan MB; Li Y; Bunin NJ; Grupp SA; Bagatell R; Seif AE
    Bone Marrow Transplant; 2016 Sep; 51(9):1204-10. PubMed ID: 27159174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of autologous hematopoietic stem cell transplantation in the treatment of high-risk neuroblastoma in children: a single-center clinical study].
    Wang LH; Chen K; Zhang N; Yang JW; Zhang T; Shao JB
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 May; 25(5):476-482. PubMed ID: 37272173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral Stem Cell Apheresis is Feasible Post
    Kraal KCJM; Timmerman I; Kansen HM; van den Bos C; Zsiros J; van den Berg H; Somers S; Braakman E; Peek AML; van Noesel MM; van der Schoot CE; Fiocco M; Caron HN; Voermans C; Tytgat GAM
    Clin Cancer Res; 2019 Feb; 25(3):1012-1021. PubMed ID: 30314967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
    Demirer T; Petersen FB; Bensinger WI; Appelbaum FR; Fefer A; Rowley S; Sanders J; Chauncey T; Storb R; Lilleby K; Buckner CD
    Bone Marrow Transplant; 1996 Jul; 18(1):29-34. PubMed ID: 8831992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens.
    Gutierrez-Delgado F; Maloney DG; Press OW; Golden J; Holmberg LA; Maziarz RT; Hooper H; Buckner CD; Appelbaum FR; Bensinger WI
    Bone Marrow Transplant; 2001 Sep; 28(5):455-61. PubMed ID: 11593318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.